Synthroid and Cannabis: What Women Need to Know About This Interaction

What the interaction actually is

The core issue is that cannabis and levothyroxine share metabolic pathways, and cannabis may also directly affect how your thyroid gland behaves. Levothyroxine itself is not heavily metabolized, but its conversion to active triiodothyronine (T3) and its clearance both involve CYP enzymes that cannabis constituents can inhibit or induce.

The enzyme story

Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are both substrates and inhibitors of CYP1A2 and CYP3A4. Levothyroxine's peripheral deiodination to T3 depends on deiodinase enzymes, and its clearance is influenced by hepatic conjugation pathways that CYP enzyme activity can modulate indirectly. CBD is a particularly potent inhibitor of CYP3A4 and CYP2C9 at clinically achievable doses, as documented in pharmacokinetic interaction studies. Smoking cannabis also induces CYP1A2, the same enzyme induced by tobacco, which can accelerate the metabolism of drugs handled by that pathway.

Direct effects on the hypothalamic-pituitary-thyroid axis

Beyond enzyme interactions, cannabinoid receptors (CB1 and CB2) are expressed in the hypothalamus and pituitary. Animal studies show that cannabinoids can suppress thyrotropin-releasing hormone (TRH) release and blunt the TSH response. A 2016 cross-sectional analysis of the National Health and Nutrition Examination Survey found that cannabis users had lower total T3 and lower TSH levels compared with non-users, though the effect sizes were modest and causality cannot be established from that design. A smaller finding, but one that matters: if cannabis is suppressing your TSH independently of levothyroxine, your clinician may misread your dose as adequate when it is not.

What this means in practice

The net effect is unpredictable at the individual level. CBD-dominant products may raise circulating levothyroxine by slowing its clearance, pushing free T4 higher than intended. Smoked THC-dominant cannabis may induce CYP1A2 enough to modestly accelerate clearance, lowering free T4. Neither effect is dramatic in most people, but for a drug with a narrow therapeutic index like levothyroxine, even small shifts matter.

Why this matters more for women

Women are five to eight times more likely than men to develop hypothyroidism, and Hashimoto's thyroiditis, the most common cause in the United States, is predominantly a female condition. That means the vast majority of people taking levothyroxine daily are women, and yet most of the pharmacokinetic data on cannabis interactions comes from studies in male-predominant or sex-unspecified populations.

Sex differences in cannabis metabolism

Women absorb THC faster, reach higher peak plasma concentrations after equivalent doses, and clear THC more slowly than men do, partly because of higher body-fat percentage and partly because of sex-hormone effects on CYP enzymes. Estrogen modulates CYP3A4 activity, and progesterone modulates CYP2C9. Both enzymes are relevant to cannabinoid metabolism. The practical consequence is that a woman and her male partner could use the same cannabis product, and she will carry a higher THC burden, potentially creating a bigger enzymatic effect on her levothyroxine handling.

The menstrual cycle dimension

Thyroid hormone levels fluctuate across the menstrual cycle. Thyroid-binding globulin (TBG) rises during the follicular phase under estrogen influence, binding more T4 and temporarily reducing free T4. If cannabis is altering free T4 levels at the same time TBG is naturally fluctuating, the combined effect on the free hormone could be clinically meaningful, even if total T4 looks stable on a blood test. Women using cannabis regularly should ideally have TSH and free T4 drawn at a consistent point in their cycle, in the early follicular phase (days 2-5), to reduce cycle-related variability in interpretation.

Here is a simplified framework for thinking about timing across the cycle:

| Cycle phase | Estrogen level | TBG effect | Free T4 effect | Cannabis interaction risk | |---|---|---|---|---| | Early follicular (days 1-7) | Low-rising | Low TBG | Free T4 relatively higher | Baseline window for testing | | Late follicular / ovulation | Peaks | TBG rises | Free T4 may dip slightly | Moderate | | Luteal (days 15-28) | Estrogen + progesterone | TBG high | Free T4 lower | Highest variability |

Perimenopause and post-menopause

Estrogen loss after menopause reduces TBG, which changes the distribution of thyroid hormone. Women transitioning through perimenopause may already have fluctuating thyroid function, and distinguishing perimenopausal symptoms (fatigue, weight gain, brain fog, irregular periods) from under-treated hypothyroidism is notoriously difficult. Adding cannabis to this picture can compound the confusion. If you are perimenopausal and using cannabis for sleep or mood, make sure your clinician knows, because the symptom overlap is real and your Synthroid dose may need adjustment during this transition.

The Menopause Society recommends against cannabis use as a first-line treatment for menopausal symptoms given insufficient safety and efficacy data, though it acknowledges that many women use it. That position is relevant context for any discussion with your clinician.

PCOS

Women with polycystic ovary syndrome (PCOS) have higher rates of thyroid autoimmunity. A 2018 meta-analysis found that Hashimoto's thyroiditis was approximately four times more prevalent in women with PCOS than in controls. PCOS also involves androgen excess, and androgens modulate CYP enzyme expression differently than estrogens do. A woman with PCOS on levothyroxine who also uses cannabis is operating with a more complex hormonal and enzymatic background than the average trial participant. Closer TSH monitoring is warranted.

Pregnancy and lactation: the non-negotiable section

Levothyroxine in pregnancy

Levothyroxine is FDA Pregnancy Category A, meaning controlled studies have shown no fetal risk. It is not only safe but essential during pregnancy. Thyroid hormone is required for fetal neurological development, particularly in the first trimester before the fetal thyroid is functional. The American Thyroid Association's 2017 guidelines for thyroid disease in pregnancy recommend that levothyroxine doses typically increase by 25-30% as soon as pregnancy is confirmed in women with pre-existing hypothyroidism. TSH should be rechecked every 4 weeks through midpregnancy.

Untreated or under-treated hypothyroidism in pregnancy is associated with increased risk of miscarriage, preterm birth, placental abruption, and impaired fetal cognitive development. This is not a minor concern.

Cannabis in pregnancy: do not use

Cannabis is contraindicated in pregnancy. Full stop. The American College of Obstetricians and Gynecologists (ACOG) advises that no amount of cannabis has been established as safe during pregnancy, and their 2023 Committee Opinion recommends that clinicians counsel women to discontinue cannabis before attempting pregnancy and throughout gestation. THC crosses the placenta. A 2020 NIH-funded prospective study found that prenatal cannabis exposure was associated with altered neurodevelopmental outcomes in children at age 9-10 in the ABCD (Adolescent Brain Cognitive Development) cohort.

If you are using cannabis to manage nausea, anxiety, or pain during pregnancy, there are evidence-based alternatives your clinician can discuss. The interaction question of Synthroid plus cannabis in pregnancy is moot because cannabis should not be part of the picture at all.

Lactation

THC is detectable in breast milk. A systematic review published in Obstetrics & Gynecology found that THC was present in breast milk for up to six days after last use in some women, and that fat-soluble cannabinoids concentrate in milk. ACOG advises against cannabis use during breastfeeding. Levothyroxine, by contrast, transfers minimally into breast milk and at levels considered safe for the nursing infant; it is compatible with lactation.

Contraception note

Levothyroxine does not require contraception and is not a teratogen. The pregnancy warning here is directed at cannabis, not at the thyroid medication.

Postpartum thyroiditis

Up to 10% of women develop postpartum thyroiditis in the year after delivery, and women with Hashimoto's antibodies are at substantially higher risk. The condition typically presents first as a transient hyperthyroid phase (weeks 1-4 postpartum), followed by a hypothyroid phase that may require temporary levothyroxine. Cannabis use during this window adds unnecessary complexity to an already hormonally volatile period and may mask or mimic symptoms of thyroid dysfunction. Avoidance is the cleaner clinical choice.

Who this applies to: right for you or not

Women for whom this interaction is particularly relevant

• You have Hashimoto's thyroiditis and take levothyroxine daily.
• You use cannabis regularly (daily or near-daily) for sleep, anxiety, pain, or recreational purposes.
• You are perimenopausal or post-menopausal and recently started cannabis for menopausal symptoms.
• You have PCOS and are on levothyroxine for concurrent thyroid disease.
• You are planning pregnancy or are currently breastfeeding.
• Your TSH has been drifting out of range without a clear explanation.

Women for whom this is lower priority

• You use cannabis occasionally (once weekly or less) and have stable TSH on a consistent dose.
• You use topical CBD products only, with minimal systemic absorption.
• You have no thyroid disease and are not on levothyroxine.

Even in the lower-priority group, if you start or stop cannabis use significantly, recheck your TSH within 6-8 weeks. Levothyroxine has a half-life of about seven days, so TSH takes 4-6 weeks to fully reflect a change in thyroid hormone levels.

Alcohol and Synthroid: the "can I drink" question

Many women ask whether they can drink alcohol while taking Synthroid. Alcohol is not a major pharmacokinetic concern for levothyroxine in the way cannabis is, but it is not irrelevant. Chronic heavy alcohol use can suppress thyroid function directly, and a 2014 meta-analysis found that chronic alcohol use was associated with reduced T3 and T4 levels and suppressed TSH independent of liver disease. Moderate alcohol consumption (one drink per day or fewer) is unlikely to meaningfully affect your levothyroxine dose. Heavy or binge drinking is a different matter, both for thyroid function and for the many other health consequences that disproportionately affect women.

Alcohol also does not change when you take your levothyroxine or require you to separate doses. The standard instruction remains: take levothyroxine on an empty stomach, 30-60 minutes before food or other medications, with water only.

Other Synthroid interactions worth knowing

Levothyroxine has numerous documented food and drug interactions. A few matter specifically to women's health.

Hormonal contraceptives and hormone therapy

Estrogen-containing contraceptives and menopausal hormone therapy raise TBG, which binds more T4 and can increase your levothyroxine dose requirement. A prospective study published in Obstetrics & Gynecology showed that women starting oral estrogen therapy often needed a levothyroxine dose increase of 25-50 mcg. Transdermal estrogen has a smaller effect on TBG. If you start or stop hormonal contraception or hormone therapy, recheck TSH within 8-12 weeks.

Common absorption disruptors

Several medications and supplements impair levothyroxine absorption when taken simultaneously. These include calcium carbonate, iron supplements (common in women with heavy periods or pregnancy), magnesium, antacids containing aluminum or magnesium, and cholestyramine. Take these at least four hours apart from levothyroxine.

Biotin

Many women take high-dose biotin for hair or nail health. Biotin at doses above 5 mg per day can falsely suppress TSH and falsely raise free T4 on immunoassay-based lab tests, mimicking hyperthyroidism or creating confusing results. Stop biotin at least 48 hours before thyroid labs.

Monitoring: a practical plan

Stable hypothyroidism is typically monitored with annual TSH testing, but the following situations call for a recheck at 6-8 weeks:

• Starting, stopping, or significantly changing cannabis use
• Starting or stopping hormonal contraception or hormone therapy
• Pregnancy confirmed or breastfeeding ended
• A new medication on the interaction list (iron, calcium, antacids, antiepileptics)
• Symptom changes: fatigue, weight change, hair loss, palpitations, mood shifts, period changes
• Switching levothyroxine brand or formulation

Free T4 should be checked alongside TSH whenever cannabis use is a factor, because TSH alone may be misleading if cannabis is independently suppressing pituitary TSH secretion.

As Dr. Elena Vasquez, MD, WomanRx's women's health editorial board member, explains: "I tell my patients that cannabis is not a neutral substance for thyroid management. We do not have the randomized trial data to quantify the interaction precisely, but the mechanistic basis is solid enough that I treat a significant change in cannabis use the same way I treat a change in a patient's estrogen status: it is a signal to recheck thyroid labs and not assume the old dose is still right."

The evidence gap: what we do not know

Women have been under-represented in cannabis pharmacology research. Most interaction data in humans comes from pharmacovigilance reports and cross-sectional surveys rather than randomized controlled trials, and most of those do not stratify by sex. The interaction between CBD-dominant products and levothyroxine has essentially no direct human trial data. The specific question of how cannabis affects levothyroxine handling across the menstrual cycle has not been formally studied. These are real gaps. The guidance above is built on mechanistic plausibility, pharmacokinetic principles, and the available observational data, not on a double-blind trial in women with Hashimoto's.

This is not a reason to panic. It is a reason to be transparent with your clinician, monitor your labs appropriately, and not assume that cannabis is pharmacologically inert for your thyroid medication.